Aurobindo Pharma receives approval for Zidovudine capsules

By Elaine Rigoli

Tampa, Fla., March 29 - Aurobindo Pharma Ltd. has received final approval for Zidovudine capsules USP 100 mg from the Food and Drug Administration.

This approval will pave the way toward marketing efforts in the United States, according to a news release.

The company already has approval of Zidovudine tablets and oral solutions.

Zidovudine is in the class of drugs called nucleoside reverse transcriptase inhibitors, which help keep the AIDS virus from reproducing. It is intended to be used with other antiretroviral agents for the treatment of HIV-1 infection.

Aurobindo is a pharmaceutical company with headquarters in Hyderabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.